Allied Market Research

2024

India Biosimilars And Follow-on Biologics Market

India Biosimilars and Follow-On Biologics Market Size, Share, Competitive Landscape and Trend Analysis Report, by Product, by Application and, by Manufacturing : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

  • Jun 2024

  • Pages: NA

  • Tables: NA

  • Charts: NA

Select an option
Cloud Access (10% Off) $3,690 $3,321
Business User License (10% Off) $5,820 $5,238
Enterprise License (10% Off) $9,870 $8,883
Library Membership (15% Off) $1,175 $999
Enquiry Now
Author's: | Roshan Deshmukh
Publish Date:
Enquire Before Buying Customization Request Speak with Analyst

Get Sample to Email

  India Biosimilars and Follow-On Biologics Market Report Highlights

Aspects Details
icon_5
By Product
  • ERYTHROPOETIN
  • GRANULOCYTE-COLONY STIMULATING FACTOR
  • GROWTH HORMONE
  • ALFA INTERFERON
  • BETA INTERFERON
  • MONOCLONAL ANTIBODY
  • FOLLITROPIN
  • Others
icon_6
By Application
  • BLOOD DISORDER
  • CANCER
  • CHRONIC AND AUTOIMMUNE DISEASE
  • GROWTH HORMONE DEFICIENCY
  • Others
icon_7
By Manufacturing
  • IN-HOUSE MANUFACTURING
  • CONTRACT MANUFACTURING ORGANIZATION
icon_8
Key Market Players

Cadila Healthcare Ltd., Reliance Life Sciences Pvt. Ltd., Wockhardt Ltd., Cipla Ltd., Intas Pharmaceuticals Ltd., Hetero Drugs Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Aurobindo Pharma Ltd., Nicholas Piramal India Ltd.

Loading Table Of Content...

India Biosimilars and Follow-On Biologics Market

Global Opportunity Analysis and Industry Forecast, 2023-2032

help@alliedmarketresearch.com